Bond.az White LogoBond.az Black Logo

Benchmark Reiterates Baidu Stock Rating on AI Revenue Milestone

Benchmark reaffirms Buy rating on Baidu after AI revenue milestone. AI Cloud margins improve, new products launched.

Sarah Johnson
BySarah Johnson- Senior Editor
|
0

Benchmark reiterated a Buy rating and $215 price target on Baidu (NASDAQ:BIDU) following the company's first-quarter 2026 results. The stock currently trades at $137.71, representing 83% of its 52-week high, and has delivered a strong 54% return over the past year.

Baidu's general business returned to positive growth in Q1 2026, with AI-driven businesses contributing more than 50% of total revenue for the first time, according to Benchmark analyst Fawne Jiang.

The firm expects the trend to continue into fiscal 2026, supported by accelerating industry-wide AI adoption and Baidu's positioning as a full-stack service provider.

Benchmark believes Baidu AI Cloud is entering a phase of structural margin improvement, driven by a higher-margin mix of GPU Cloud and AI applications, alongside ongoing operating expense optimization and stronger discipline.

The firm cited asset value unlocking as a rerating catalyst, including the upcoming Kunlun spin-off, Apollo Go global scaling, Hong Kong dual-primary listing plans, and continued shareholder returns.

More News
Today / 12:32
|
795

Morgan Stanley Reiterates Home Depot Rating on Execution

Morgan Stanley reiterates Overweight rating on Home Depot with $420 target, citing solid execution in a growthless housing market.

0
Today / 12:31
|
212

Compass Point Lowers DeFi Tech Target

Compass Point cuts DeFi Technologies price target to $1.45, maintains Buy rating amid bear market.

0
Today / 12:04
|
952

Raymond James Backs Nutrien Stock on Potash

Raymond James backs Nutrien stock with Outperform rating and $90 target after Indian potash deal. 26% upside, strong financials.

0
Today / 11:35
|
858

Mizuho Raises STM Price Target on AI Growth

Mizuho raises STMicroelectronics price target to $68, citing AI growth and new technologies.

0
Today / 11:03
|
967

Oppenheimer Reiterates Outperform on UroGen Pharma

Oppenheimer reiterates Outperform on UroGen Pharma with $40 target. Strong commercial momentum for Zusduri driven by physician enthusiasm.

0
Today / 11:02
|
510

Guggenheim Upgrades StubHub Stock on Reset

Guggenheim upgrades StubHub stock to Buy with a $12.50 price target, citing reset expectations and growth catalysts like the World Cup.

0
Today / 10:31
|
290

Wolfe Research Initiates CytomX Stock with Outperform

Wolfe Research initiated CytomX Therapeutics (CTMX) with an outperform rating and $3.50 target. Varseta-M shows promise in colorectal cancer.

0
Today / 10:30
|
842

Wolfe Research initiates Mirum with outperform

Wolfe Research starts Mirum Pharmaceuticals with outperform rating and $145 price target, citing strong pipeline potential.

0
Today / 10:14
|
236

Wolfe Research Initiates Oklo with Peerperform

Wolfe Research initiated Oklo Inc. with a Peerperform rating. Learn about the company's targets, finances, and stock performance.

0
Today / 10:13
|
631

Aletheia Capital Reaffirms Circle Stock Rating

Aletheia Capital reaffirms Buy rating on Circle Internet Group amid U.S. stablecoin regulatory advantages. Stock at $111.39.

0
Today / 09:31
|
784

Jefferies Initiates X-Energy Stock with Hold Rating

Jefferies initiates X-Energy stock coverage with a Hold rating and $28 target. Learn about risks and recent performance.

0
Today / 09:11
|
441

UBS Upgrades Jazz Pharma on Ziihera Potential

UBS upgrades Jazz Pharmaceuticals to Buy with a $307 target on Ziihera potential. Bond.az provides detailed analysis and stock insights.

0
...